Bulletin from the extraordinary general meeting in Ascelia Pharma AB


Today, on 13 April 2021, an extraordinary general meeting was held in Ascelia Pharma AB. A sum-mary of the adopted resolutions follows below. In light of the ongoing Covid-19 pandemic and in order to reduce the risk of infection spreading, the meeting was held only by advance voting (postal vote) in accordance with temporary legislation.

The English text is an unofficial translation. In case of any discrepancies between the Swedish text and the English translation, the Swedish text shall prevail.

Resolution on approval of the board of directors’ resolution on directed issue of shares
The meeting resolved to approve the board of directors’ resolution of 17 March 2021 to increase the company’s share capital with not more than SEK 5,000,000 through the issue of not more than 5,000,000 ordinary shares. Through the directed issue of shares, the company will receive SEK 200 million before transaction costs. The net proceeds are intended to be used for (i) financing the Phase 2 study for the oral chemotherapy drug candidate Oncoral, (ii) accelerating activities towards the commercialization of the diagnostic drug Mangoral, currently in an ongoing Phase III study and (iii) general corporate purposes.


Ascelia Pharma’s Food Effect Study with Orviglance successfully completed

Ascelia Pharma AB (publ) (ticker: ACE) today announced that the last patient visit has been completed in the study to evaluate the effect of food intake on the absorption of Orviglance (Mangoral). This Food Effect Study is part of the ongoing pivotal clinical program for Orviglance and will be included in the marketing authorization package to the health authorities including FDA and EMA.

Ascelia Pharma Signs Clinical Collaboration Agreement With Taiho Oncology, Inc. for the Development of Oncoral in Combination with LONSURF®

Ascelia Pharma AB (publ) (ticker: ACE) today announced that it has signed a clinical collaboration agreement with Taiho Oncology Inc., a subsidiary of Taiho Pharmaceutical Co., Ltd. The collaboration concerns an upcoming global Phase 2 clinical study in gastric cancer. In this all-oral combination study, Ascelia Pharma’s irinotecan chemotherapy tablet Oncoral (ASC-201) will be evaluated in combination with Taiho Oncology’s LONSURF® (trifluri ...

Quarterly Report Q2 2021: Preparing Oncoral for the next level

Ascelia Pharma AB (publ) (ticker: ACE) today published its quarterly financial report for Q2 2021 (April – June 2021), which is now available on the company’s website: